HIV

Sunlenca® (lenacapavir) Receives FDA Approval as a First-in-Class, Twice-Yearly Treatment Option for People Living With Multi-Drug Resistant HIV

By
1 Mins read
94
0
Share
Reading Time: < 1 minute

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that Sunlenca® (lenacapavir), in combination with other antiretroviral(s) (ARV), has been granted approval by the U.S. Read More

94
0
Share
Related posts
HIV

HIV warning issued by UKHSA as diagnosis rate jumps by more than 30%

By
1 Mins read
Reading Time: < 1 minute Startling new data warns that HIV cases may be on the rise in England, serving as a ‘crucial reminder’ that we must safeguard…
HIV

Ex-SANDF employee sentenced to life for rape and infecting ex with HIV

By
1 Mins read
Reading Time: < 1 minute An ex-South African National Defence Force (SANDF) employee has been sentenced to life for raping his girlfriend and an additional 10 years…
HIV

HIV+ Zanu-PF MP up for raping ex-wife at gunpoint

By
1 Mins read
Reading Time: < 1 minute Tsungai Makumbe, a prominent member of Zimbabwe’s ruling ZANU PF party and MP for Mazowe North, has been brought before the court…
Subscribe to our Blog

Let's stay in touch. Subscribe to our blog and get our best content in your inbox. 

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.